"在医疗建议"离开医院之前和随后的药物过量服用:基于人口的队列研究
Mayesha Khan1, Xiao Nicole1, Alexis Crabtree1
1Departments of Medicine (Khan, Hu, Nasmith, Daly-Grafstein, Staples), Statistics (Hu, Daly-Grafstein), Emergency Medicine (Moe, Brubacher), and School of Population and Public Health (Crabtree, Slaunwhite), University of British Columbia; BC Centre for Disease Control (Crabtree, Moe); Centre for Clinical Epidemiology & Evaluation (Staples); Centre for Advancing Health Outcomes (Staples, Slaunwhite); BC Mental Health and Substance Use Services (Slaunwhite), Vancouver, BC.
在医疗建议 (BMA) 释放之前离开医院的患者面临着在30天内过量服用药物的明显更高风险. 这项研究强调迫切需要更好的物质使用障碍治疗和出院后的支持,以防止过量服用.
科学领域:
- 公共卫生 公共卫生
- 成 药物 药物 药物 药物
- 医疗保健服务研究 医疗服务研究
背景情况:
- 许多患者在完成医疗治疗之前离开医院.
- 过早离开护理和随后的药物过量风险之间的关联尚未得到充分理解.
研究的目的:
- 为了调查致命或非致命的非法药物过量剂量的风险,在医疗建议 (BMA) 释放后的30天内与医生建议的释放相比,在医疗建议 (BMA) 释放后的30天内.
主要方法:
- 使用加拿大不列颠哥伦比亚省 (2015-2019) 的行政卫生数据进行的回顾性队列研究.
- 使用生存分析来比较出院后前30天的过量剂量率.
- 专注于非选择性,非产科性住院.
主要成果:
- 3.4%的住院时间以BMA出院结束.
- BMA排放与未经调整的过量剂量率高出10倍 (2.8%vs0.3%) 和后续过量剂量的调整危险比率为1.58.
- 此外,BMA释放也增加了紧急部门访问和计划外再接收的风险.
结论:
- 在医疗建议出院之前显著提高了在出院后的30天内药物过量服用的风险.
- 干预措施,如增强药物使用障碍治疗,扩大过量预防服务和出院后宣传,对于减轻这种风险至关重要.
更多相关视频
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
06:52Assessment of Dependence in Activities of Daily Living Among Older Patients in an Acute Care Unit
Published on: September 30, 2020
相关概念视频
Factors Affecting Drug Response: Overview
Drug Abuse and Addiction: Pharmacological Phenomena
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Drug Dependence
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Regulation
